Characteristics of COVID-19 Patients in Kazakhstan in Early 2020
2020年11月12日 更新者：Semey State Medical University
Epidemiological and Clinical Characteristics of COVID-19 Patients in Kazakhstan in Early 2020: a Retrospective, Observational Cohort Study
The aim of this study is to assess the epidemiological and clinical features of patients diagnosed with COVID-19 in Kazakhstan at the onset of the pandemic.
研究概览
详细说明
There is a paucity of data available on the epidemiological and clinical characteristics of coronavirus disease 2019 (COVID-19) in Kazakhstan.
While a global effort in search for effective treatments and vaccines against COVID-19 is in effect, it is important that high quality and up-to-date information be available from a broad variety of populations on the dynamics of infection.
This is especially important in regions where, due to resource shortage, epidemiologic surveillance may have gaps.
To address the current gaps, medical records will be obtained for patients with confirmed COVID-19 during the first months of the pandemic (February-April 2020).
The epidemiologic and clinical features including the demographics, clinical manifestation, laboratory parameters, radiologic assessments and clinical outcomes will be analyzed.
The results of this study will facilitate the clinical management of COVID-19 patients in Kazakhstan and ultimately inform the ongoing efforts to curb the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the region.
研究类型
观察性的
注册 (预期的)
1000
联系人和位置
本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。
学习地点
-
-
East Kazakhstan
-
Semey、East Kazakhstan、哈萨克斯坦
- Semey Medical University
-
-
参与标准
研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
1秒 及以上 (孩子、成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
取样方法
概率样本
研究人群
Medical records will be obtained for all subjects, who presented with COVID-19-like symptoms or had a suspected exposure to SARS-CoV-2 between Feb 20 and April 30, 2020 as reported to the Republican Centre for Health Development by regional hospitals.
Only those patients who had a positive SARS-CoV-2 PCR test result will be included in the analysis of primary and secondary outcome measures.
描述
Inclusion Criteria:
- Laboratory confirmation of SARS-CoV-2 infection by polymerase chain reaction.
学习计划
本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。
研究是如何设计的？
设计细节
队列和干预
团体/队列 |
|---|
|
Mild and asymptomatic COVID-19 patients
Symptomatic patients meeting the World Health Organization (WHO) case definition for COVID-19 without evidence of viral pneumonia or hypoxia, who have a laboratory-confirmed SARS-CoV-2 infection, or asymptomatic patients with a laboratory-confirmed SARS-CoV-2 infection at the time of hospitalization.
|
|
Moderate severity COVID-19 patients
Symptomatic patients with a laboratory-confirmed SARS-CoV-2 infection, meeting the WHO case definition for moderate COVID-19 disease severity [including clinical signs of pneumonia e.g.
fever, cough, dyspnoea, fast breathing, but no signs of severe pneumonia] at the time of hospitalization.
|
|
Severe-to-critical COVID-19 patients
Symptomatic patients with a laboratory-confirmed SARS-CoV-2 infection, meeting the WHO case definition(s) for severe COVID-19 disease presentation [including clinical signs of pneumonia e.g.
fever, cough, dyspnoea, fast breathing, and one of the following: respiratory rate > 30 breaths/min; severe respiratory distress; or oxygen saturation (SpO2) < 90% on room air] or for critical COVID-19 disease presentation [including acute respiratory distress syndrome (ARDS), sepsis, septic shock or other complications such as acute pulmonary embolism, acute coronary syndrome, acute stroke and delirium] at the time of hospitalization.
|
|
COVID-19 survivors
Patients diagnosed with a laboratory-confirmed COVID-19, who survived.
|
|
COVID-19 non-survivors
Patients diagnosed with a laboratory-confirmed COVID-19, who did not survive.
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Clinical and demographic predictors of disease severity among hospitalized COVID-19 patients.
大体时间：approximately 70 days
|
Risk factors associated with disease severity and their odds ratios (ORs) will be assessed by the univariable and multivariable logistic regression models.
|
approximately 70 days
|
|
Clinical and demographic predictors of mortality among hospitalized COVID-19 patients.
大体时间：approximately 70 days
|
Risk factors associated with death and their odds ratios (ORs) will be assessed by the univariable and multivariable logistic regression models.
|
approximately 70 days
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 学习椅：Yersin Zhunussov, MD, D.M.S.、Semey State Medical University
- 研究主任：Raifa Ivanova, MD, D.M.S.、Semey State Medical University
- 首席研究员：Maiya Goremykina, M.D, C.M.S、Semey State Medical University
- 首席研究员：Sergey Yegorov, Ph.D.、Nazarbayev University, School of Sciences and Humanities
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2020年2月20日
初级完成 (实际的)
2020年4月30日
研究完成 (预期的)
2020年12月1日
研究注册日期
首次提交
2020年11月6日
首先提交符合 QC 标准的
2020年11月12日
首次发布 (实际的)
2020年11月13日
研究记录更新
最后更新发布 (实际的)
2020年11月13日
上次提交的符合 QC 标准的更新
2020年11月12日
最后验证
2020年11月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.